Drug
C-CAR088
C-CAR088 is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
5
100%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(1)
Other(3)
Detailed Status
unknown3
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 15 (100.0%)
Trials by Status
unknown360%
completed120%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
completedphase_1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
NCT04322292
recruitingphase_1
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
NCT05632380
unknownphase_1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
NCT04295018
unknownphase_1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
NCT03815383
unknownphase_1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
NCT03751293
Clinical Trials (5)
Showing 5 of 5 trials
NCT04322292Phase 1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
NCT05632380Phase 1
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
NCT04295018Phase 1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
NCT03815383Phase 1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
NCT03751293Phase 1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5